Before choosing a provider, check who answers clinical questions, when that route is staffed, what information the team asks for, and where it directs patients when help cannot wait. “Message us if worried” is not a complete follow-up policy.
Why side-effect follow-up matters
The current UK patient information leaflets for Mounjaro and Wegovy describe both commonly reported effects and less common warnings that require prompt or urgent medical attention. They also tell patients to report suspected side effects through the MHRA Yellow Card scheme. A clinic does not need to reproduce every warning on its sales page, but it should make the route to appropriate help visible.
This is not about expecting a private clinic to operate as an emergency service. It is about knowing the limits of its service before a problem arises. A provider should distinguish routine follow-up from urgent NHS help and explain what happens outside its normal opening hours.
What should be clear before you pay?
- Clinical responsibility: who reviews side-effect messages — a prescriber, pharmacist, nurse or another named clinical team?
- Contact method: is support reached by telephone, secure message, app or email, and is it separate from general customer service?
- Response window: does the provider state when the route is monitored, including evenings, weekends and bank holidays?
- Review process: does it explain when a follow-up review is arranged and how treatment decisions are documented?
- Urgent boundaries: does it clearly say that emergency or urgent concerns should not wait in a sales inbox or routine callback queue?
- Reporting: does it signpost the official MHRA Yellow Card route for suspected adverse reactions?
NICE's guideline on overweight and obesity management says the effect of weight-management medicines should be monitored through regular review, alongside behavioural advice and adherence. That supports a simple comparison principle: ongoing prescribing should come with an intelligible review process, not merely a repeat checkout.
What information is useful when contacting the service?
A provider should say what it needs in order to assess a message safely. Useful factual details can include the medicine and presentation shown on the label, when the problem began, what has changed, any other medicines involved, and the dispensing pharmacy or batch details where relevant. The clinic should collect this through an appropriate clinical channel rather than encouraging people to post private health information publicly.
Recording facts is not the same as diagnosing the cause. A symptom occurring during treatment is not automatically caused by the medicine. The clinical team, official patient leaflet and appropriate NHS service each have a different role.
How should urgent and out-of-hours help be explained?
The NHS says 111 can help when someone thinks they need medical help right now and can direct them to the appropriate service, including when a GP is closed. The NHS says 999 is for life-threatening emergencies. The patient leaflets also contain medicine-specific warnings telling readers when to contact a doctor or seek urgent medical help.
A clinic's public information should point to those official routes without inventing its own symptom-scoring system. It should not imply that a routine message will be read immediately, or that contacting the clinic replaces urgent care. For personal decisions, use the current leaflet supplied with the medicine and seek advice from an appropriate healthcare professional or NHS service.
Where does Yellow Card fit?
The MHRA Yellow Card scheme collects suspected adverse drug reaction reports and other healthcare-product safety concerns. Patients, carers and healthcare professionals can report. A report helps the regulator monitor safety signals; it does not prove that a medicine caused a particular symptom, provide emergency care or replace the clinic's follow-up responsibility.
A provider that mentions Yellow Card should still explain who handles the immediate clinical question. Those are separate jobs: one supports UK medicines safety monitoring, while the other concerns the person's care now.
Weak follow-up signals to notice
- side-effect support is promised but no staffed hours or clinical owner are named;
- the only contact route leads to sales or delivery support;
- repeat orders are prominent but medicine reviews are not explained;
- urgent questions are directed to social media, a public group or an unmonitored email address; or
- the service gives reassurance without linking to current patient information or official NHS help.
None of these points ranks a clinic or proves that care is poor. They show where the public trail is incomplete and where a direct question is sensible before committing.
Sources
- electronic Medicines Compendium. Mounjaro KwikPen — Patient Information Leaflet. Read the current UK leaflet.
- electronic Medicines Compendium. Wegovy FlexTouch — Patient Information Leaflet. Read the current UK leaflet.
- MHRA. The Yellow Card scheme: guidance for healthcare professionals, patients and the public. Read the guidance.
- NHS. When to use NHS 111 and when to call 999.
- NICE. Overweight and obesity management (NG246): medicines and surgery. Read the recommendations.